Studies in a variety of U.S. clinical laboratories have demonstrated difficulty in detecting intermediate and low-level vancomycin-resistant enterococci (VRE).
The misclassification of « at least intermediate resistant isolates » as vancomycin susceptible may have both clinical implications and a negative impact on measures to control the spread of VRE.
No published study has assessed the ability of clinical laboratories in Europe to detect VRE.
So, the apparent low prevalence of VRE in European hospitals may be, in part, secondary to the inability of these laboratories to detect all VRE.
In an effort to assess European laboratories'proficiency in detecting VRE, we identified 22 laboratories in Spain and asked them to test four VRE strains and one susceptible enterococcal strain from the Centers for Disease Control and Prevention collection.
Each organism was tested by the routine antimicrobial susceptibility testing method used by each laboratory.
Overall, VRE were correctly identified in 61 of 88 (69.1%) instances.
The accuracy of VRE detection varied with the level of resistance and the antimicrobial susceptibility method.
The high-level-resistant strain (Enterococcus faecium ; MIC, 512 mug/ml) was accurately detected in 20 of 22 (91.3%) instances, whereas the intermediate-resistant isolate (Enterococcus gallinarum ; MIC, 8 mug/ml) was accurately detected in only 11 of 22 (50%) instances.
Classification errors occurred in 27 of 88 (30.9%) instances. (...)
Mots-clés Pascal : Enterococcus, Streptococcaceae, Micrococcales, Bactérie, Antibiotique, Antibactérien, Résistance, Dépistage, Détection, Laboratoire, Test sensibilité médicamenteuse, Concentration minimale inhibitrice, Evaluation performance, Vancomycine, Europe Sud, Europe, Glycopeptide, Peptide, Espagne, Souche résistante vancomycine
Mots-clés Pascal anglais : Enterococcus, Streptococcaceae, Micrococcales, Bacteria, Antibiotic, Antibacterial agent, Resistance, Medical screening, Detection, Laboratory, Drug susceptibility test, Minimum inhibitory concentration, Performance evaluation, Vancomycin, Southern Europe, Europe, Glycopeptide, Peptides, Spain
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0385183
Code Inist : 002A05B14. Création : 22/03/2000.